Transitioning streetrecruited heroin users to HCV treatment using buprenorphine

NIDA DA015629-01

Diana Sylvestre, MD
University of CA, San Francisco
OASIS (Organization to Achieve Solutions in Substance-Abuse)


HCV and addiction: an insurmountable problem?

- 70% of IDUs in US exposed
 - Easily transmitted
- Treatment can be toxic
 - Often "contraindicated"
 - Medical
 - Psychiatric
- Reinfection?

A different perspective


| | Addiction | HCV |
|-----------------------|------------|-------------|
| Pharmacologic therapy | Yes (+/-) | Yes |
| Treatment duration | Indefinite | 24-48 weeks |
| Cure | No | Yes |

Natural history: addiction



Hser, Y. I., et al. (2001) Arch Gen Psychiatry, 58, 503-8.

Natural History of HCV Infection



NIH Management of Hepatitis C Consensus Conference Statement. June 10-12, 2002. Available at: http://consensus.nih.gov/2002/2002HepatitisC2002116html. Accessed April 10, 2007.

How should we intervene?

Priority

- Addiction?
- HCV?

Priority

- Diabetes?
- High blood pressure?




- Diabetes AND high blood pressure
- Addiction AND hepatitis C

HCV Treatment Recommendations: 2002

"HCV therapy has been successful even when the patients have not abstained from continued drug or alcohol use... Thus, it is recommended that treatment of active injection drug use be considered on a caseby-case basis, and that active injection drug use in and of itself not be used to exclude such patients from antiviral therapy." -- NIH Consensus Statement on HCV, 2002


HCV Treatment in Methadone Patients

SVR Rates in Injection Drug Users on Methadone Detox (N = 50)



HCV Treatment Outcomes in Methadone Patients


■ Patients on methadone maintenance (n=50) ■ Controls (n=50)



Mauss S, et al. Hepatology. 2004;40:120-124.

HCV Treatment Outcomes in Methadone Patients


Degree of Drug Use and SVR (N = 76)



Sylvestre DL, et al. J Subst Abuse Treatment. 2005;29:159-165.

HCV Treatment in the Setting of Active Drug Use

HCV Treatment Outcomes: Active IDUs vs Nonactive IDUs (N = 406)



Approaches to Intervention:

O.A.S.I.S. Study

Our setting









Our situation

- Poverty, high rates of drug use
 - Heroin, crack cocaine, methamphetamine
- Very high HCV seroprevalence
 - -~95% of IDUs
- Low rates of health insurance
 - Limited access to medical care
 - Limited access to drug treatment
- Syringe exchange is disliked but tolerated
 - (usually)





Hypothesis

 Active, street-recruited heroin users can be safely and successfully treated for hepatitis C after 12-24 weeks of buprenorphine stabilization.

Study Design

Heroin Users at Syringe Exchange

Hepatitis C Viral Testing

Inactive: Ineligible

Active: 12-24 weeks buprenorphine

Not Interested in HCV Treatment: 12 wk buprenorphine taper

HCV Treatment, n=50
Buprenorphine Maintenance

24 week buprenorphine taper


Criteria for initiating HCV treatment

- -Active HCV
- -Interested
- Attendance of >75% of weekly education sessions

Enrollment

- All screened = 415
- Eligible = 275
 - Ineligible = 140 (33%)
 - Not viremic = 94 (23%)
 - On methadone = 29 (7%)
 - No opioid addiction = 17 (4%)

Relevance All Screened: n=415



The study sample is representative


| | Screened | Eligible | Enroll | Start Study Meds | P Value |
|--------|----------|----------|---------|------------------------|---------|
| n | 415 | 275 | 188 | 146 | |
| Age | 46 | 46 | 46 | 46 | NS |
| | (20-69) | (24-69) | (24-64) | (24-64) | |
| Male | 70.4% | 74.9% | 73.9% | 71.2% | NS |
| White | 34.5% | 32.0% | 31.9% | 33.6% | NS |
| Black | 37.3% | 40.0% | 39.4% | 41.8% | NS |
| Latino | 23.9% | 23.6% | 23.4% | 19.2% | NS |

The study sample is representative


| | Screened | Eligible | Enroll | Start Bupe | P Value |
|-------------|----------|----------|--------|---------------|---------|
| Yr. exposed | 24 | 25 | 25 | 25 | |
| ALT | 46 | 53 | 55 | 54 | <0.001* |
| % Cocaine | 47.5 | 50.6 | 48.6 | 50.0 | NS |
| % Methamp | 15.6 | 14.9 | 13.5 | 13.2 | NS |
| % Alcohol | 58.0 | 50.3 | 60.1 | 55.5 | NS |

^{*}Significant for the difference between screened and eligible cohorts

Drug Use Week 0-12




Treatment Retention (n=146)



Interest in HCV Treatment


Interest in HCV Treatment



HCV Treatment Outcomes

- Completed treatment, n=37
- Early termination, n=18
 - -3 incarcerated
 - -4 medical
 - 10 failed to show
 - 1 side effects


HCV Treatment Outcomes




Outcomes by Genotype



Relevance to heroin users who initiate buprenorphine



Relevance to all eligible heroin users




Current Questions

- Can we predict who will successfully complete HCV treatment?
- Can we predict who will initiate HCV treatment?
- How can we maximize engagement and outcomes?

Acknowledgments

- NIDA
- OASIS Staff
 - Christopher McNeil
 - Laphyne Barrett
- East Bay Community Recovery Project



"I'm starting to really like the smell of cocaine."